Report cover image

Generative AI in Drug Discovery: Accelerating R&D Timelines & Cost Reduction

Publisher ResearchCubes
Published Mar 31, 2026
Length 44 Pages
SKU # RCUB21142017

Description

This strategic assessment examines how AI-driven molecular design, virtual screening, and target identification are compressing drug discovery cycles from 10+ years to 3-5 years with measurable cost reduction. The report analyzes the Lilly-NVIDIA partnership model, benchmarks AI platform capabilities, assesses integration with existing R&D workflows, and identifies organizational barriers to adoption. Key findings include AI proving 30-40% faster hit identification, reducing wet-lab testing by 50%, and accelerating go-to-market advantage. The report provides a roadmap for pharma R&D leaders to evaluate AI partnerships, build internal capabilities, and position their organizations for competitive advantage in discovery.

Table of Contents

44 Pages
EXECUTIVE SUMMARY
1.1 Methodology & AI Landscape in Drug Discovery
1.2 The Patent Expiry Crisis: Why AI Acceleration Matters
1.3 Key Findings: Timeline Compression, Cost Reduction, Competitive Impact
AI IN DRUG DISCOVERY MATURITY FRAMEWORK
2.1 Four Stages: From Research Tools to Strategic Competitive Moat
2.2 Capability Assessment: Computational Models, Target ID, Lead Optimization
2.3 Organizational Readiness: Skills, Infrastructure, Change Management
2.4 Peer Benchmarking (Top 20 Pharma R&D Programs)
STRATEGIC IMPERATIVES FOR 2026
3.1 AI-Driven Target Identification: 50%+ Timeline Reduction
3.2 Virtual Screening & Molecular Design: Reducing Wet-Lab Burden
3.3 Synthetic Biology & Novel Modalities: New Therapeutic Frontiers
3.4 Data Integration: Genomics, Structural Biology, Literature Mining
3.5 Regulatory Readiness: FDA Expectations for AI-Discovered Compounds
AI-POWERED DRUG DISCOVERY: EXECUTION & BEST PRACTICES
4.1 Technology Stack: Molecular Dynamics, Generative Models, Docking
4.2 Lilly-NVIDIA Supercomputer Model: Partnership, Infrastructure, Results
4.3 In Silico Target Validation: Early Stage Risk Reduction
4.4 Case Study: AI-Accelerated Antibody Discovery (Genentech Example)
4.5 Case Study: Novel Modalities & Engineered Proteins
PLATFORM SELECTION & VENDOR LANDSCAPE
5.1 AI Drug Discovery Platform Evaluation (10 Platforms Benchmarked)
5.2 Build vs. Partner vs. Acquire: Strategic Decision Framework
5.3 Data Governance & IP Protection in AI Collaborations
5.4 Integration with Existing R&D Infrastructure
24-MONTH AI DISCOVERY PROGRAM ROADMAP
6.1 Phase 1 (Months 1-8): Capability Assessment & Pilot Launch
6.2 Phase 2 (Months 9-18): Platform Deployment & Team Reskilling
6.3 Phase 3 (Months 19-24): Portfolio Impact & Competitive Advantage
6.4 Investment, Expected Returns & Risk Mitigation
APPENDICES
A. AI in Discovery Maturity Assessment Tool
B. Vendor Platform Evaluation Matrix
C. Partnership Agreement Framework (Lilly Model Analysis)
D. Team Composition & Upskilling Roadmap
E. Budget Model & Expected ROI (Per-Program Impact)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us